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Abstract 
Inactivating mutations in the MLH1 gene cause the cancer predisposition Lynch syndrome, 
but for small coding genetic variants it is mostly unclear if they are inactivating or not. Nine 
such MLH1 variants have been identified in South American colorectal cancer (CRC) patients 
(p.Tyr97Asp, p.His112Gln, p.Pro141Ala, p.Arg265Pro, p.Asn338Ser, p.Ile501del, 
p.Arg575Lys, p.Lys618del, p.Leu676Pro), and evidence of pathogenicity or neutrality was 
not available for the majority of these variants. We therefore performed biochemical 
laboratory testing of the variant proteins and compared the results to protein in-silico 
predictions on structure and conservation. Additionally, we collected all available clinical 
information of the families to come to a conclusion concerning their pathogenic potential and 
facilitate clinical diagnosis in the affected families. We provide evidence that four of the 
alterations are causative for Lynch syndrome, four are likely neutral and one shows 
compromised activity which can currently not be classified with respect to its pathogenic 
potential. The work demonstrates that biochemical testing, corroborated by congruent 
evolutionary and structural information, can serve to reliably classify uncertain variants when 
other data are insufficient. 
 
Key words 
Lynch syndrome, MLH1, small coding variant, variant of uncertain significance, 
pathogenicity classification 
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Introduction 
Lynch syndrome (MIM #120435) is a heritable condition associated with a greatly increased 
lifetime risk of colorectal cancer (CRC) (70-80%), endometrial cancer (50-60%), stomach 
cancer (13-19%), ovarian cancer (9-14%), cancer of the small intestine, the biliary tract, brain 
as well as carcinoma of the ureters and renal pelvis ⁠
1
. It is caused by an inactivating mutation 
of a DNA mismatch repair (MMR) gene: MLH1 (MIM# 120436), MSH2 (MIM #609309), 
MSH6 (MIM #600678), and PMS2 (MIM #600259) or to deletions of the 3’ portion of the 
EPCAM gene ⁠
2,3
.  
Since Lynch syndrome does not provide a characteristic phenotype enabling clinical 
diagnosis, diagnosis requires identification of a causative (inactivating) mutation in a MMR 
gene. Besides establishing the diagnosis for the affected patient, this subsequently enables 
predictive testing of family members, and therefore early surveillance and cancer prevention 
methods provide significant benefit for affected individuals. 
While the relevant genes are known and tools for detecting genetic alterations are readily 
available, a significant proportion of alterations identified in patients cannot straightforwardly 
be classified as inactivating and therefore pathogenic ⁠
3,4
. This exemplarily accounts for many 
small coding variants like missense alterations and small insertions or deletions, as well as for 
non-coding variants outside the highly conserved splicing motifs which may affect splicing in 
an unpredictable fashion. For these variants, pathogenicity clarification must be performed. 
Different lines of evidence, either directly from clinical patient or family data, or indirect, 
from laboratory or in silico predictions, may be used. Different approaches have been 
suggested to solve this problem ⁠
5
, and for some lines of evidence, likelihood ratios (LRs) have 
been determined to integrate evidence into a probability score ⁠
6
 of pathogenicity which allows 
classification in a 5-tiered system ⁠
4
, ideally yielding a clear classification of a variant. 
However, for other types of small coding variants, as well as for so-called private variants for 
which sufficient appropriate information is usually lacking, pathogenicity classification 
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requires alternative procedures. In these cases, it is possible to perform functional testing to 
assess the impact of a variant, which has frequently served to approach a classification for 
such variants ⁠
5,7–10
. 
We have previously shown that small, coding variants most frequently cause destabilization 
and/or inactivation of the resulting MLH1 protein, and provided reference variants that 
facilitate translation of biochemical test results in pathogenicity information 
11
.  
Genetic counselling and testing has recently been introduced in Latin America and has led to 
the identification of several yet uncharacterized genetic variants in MLH1 
12
. In this work, we 
have tested nine small coding variants identified in 9 South American individuals. We 
describe the experimental evaluation of their effects at protein level. We further discuss the 
results in context with all the available clinical information that has been gathered from the 
affected patients and their families, and also assess the structural role of the altered residues 
and their conservation in evolution. While biochemical data alone is not yet considered fully 
sufficient for variant classification, we show that information from different lines of evidence 
was consistent and strongly supported conclusions prompted by the biochemical results. Thus, 
we found that four alterations which disrupt protein function are causative for Lynch 
syndrome, while another four are likely neutral. Only one alteration evaded classification due 
to unclear biochemical results and therefore requires further analyses. 
 
Materials/Subjects and Methods. 
South American cancer families. 
Unpublished data from hereditary cancer registries and published data from patients with 
suspected Lynch syndrome have been included in this work. The data include results from 
germline DNA testing, tumor testing (based on microsatellite instability analysis and/or 
immunohistochemistry) and family history 
12–15
. 
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Families that fulfilled the Amsterdam criteria and/or the Bethesda guidelines 
16–18
 were 
selected from 4 hereditary cancer registries: Hospital Italiano (Buenos Aires, Argentina), 
Barretos Cancer Hospital (Barretos, Brazil), Clinica Las Condes (Santiago, Chile), and 
Hospital de las Fuerzas Armadas (Montevideo, Uruguay).  
Patients were informed about their inclusion into the registries and written informed consent 
was obtained from all participants during genetic counseling sessions. 
 
Nomenclature and classification of genetic variants. 
The nomenclature guidelines of the Human Genome Variation Society (HGVS) were used to 
describe the detected genetic variants 
19
. The recurrence of the identified variants was 
established by interrogating four databases (in their latest releases as of September 2017): the 
Leiden Open Variation Database (LOVD), the Universal Mutation Database (UMD), ClinVar 
and the Human Gene Mutation Database (HGMD). The variants were classified according to 
the 5-tier classification system into the following categories: class 5 (pathogenic), class 4 
(likely pathogenic), class 3 (uncertain variants or variants of unknown significance, VUS), 
class 2 (likely not pathogenic) and class 1 (not pathogenic) ⁠
4
. Syntax of all variants was 
verified using Mutalyzer 
20
 using the current MLH1 reference sequence (NM_000249.3). 
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Cell lines.  
HEK293T cells were used for this work and were kindly provided by Prof. Josef Jiricny, 
Zürich, Switzerland, in the year 2001. Their identity was confirmed by comparison of its 
genomic short tandem repeat (STR) profile from 9 loci with the source HEK293T cell line 
DSMZ ACC 635 and further confirmed by a variable number tandem repeat (VNTR) profile 
by the Leibnitz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany.  
 
Protein expression and quantification.  
pcDNA3-MLH1, pSG5-PMS2, and the HEK293T cell line have been described previously 
21,22
. Missense variants were generated by site-directed mutagenesis (QuikChange II Kit, 
Stratagene) and confirmed by direct sequencing. HEK293T cells were transiently transfected 
with 5 µg of vector DNA and 20 µl of polyethyleneimine (1 mg/ml, "Max" linear, 40 kDa, 
Polysciences,Warrington, PA) and extracted as described previously 
11,23
. The extracts were 
analyzed by SDS-PAGE and immunoblotting (using anti-MLH1, G168-728, BD Biosciences, 
and anti-PMS2, E-19, and anti-beta-Actin, C2, from Santa Cruz Biotechnologies). 
Chemiluminescence signals (Immobilon, Millipore) were detected in an LAS-4000 mini 
camera (Fuji) and quantified using Multi Gauge v3.2.  
 
Evaluation of expression defects with respect to pathogenicity.  
Protein expression and quantification were performed in parallel with a stability-impaired 
neutral control variant (MLH1 p.Val716Met) and a severely destabilized pathogenic control 
variant (MLH1 p.Ala681Thr) as described before 
11
. A clinically pathogenic defect of protein 
stability is present when the expression of the variant in question was similar or below that of 
the pathogenic control variant as extensively demonstrated before ⁠
9,11
. 
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MMR activity.  
The MMR activity of MLH1 variants was scored in vitro as described previously 
11,23
. Briefly, 
protein extracts were mixed with 35 ng of DNA substrate containing a G-T mismatch and a 3’ 
single-strand nick at a distance of 83 bp. After incubation at 37 °C, the DNA substrate was 
purified and digested with EcoRV and AseI. The restriction fragments were separated in 
agarose gels and analyzed using GelDoc XR plus detection and QuantityOne software (Bio-
Rad). The repair efficiency (e) was calculated as: e = (intensity of bands of repaired substrate) 
/ (intensity of all bands of substrate). This result is independent of the amount of DNA 
recovered through plasmid purification. The typical total repair efficiencies ranged from 50-
90%. The repair efficiency of MLH1 variants was analyzed in direct comparison to a wild-
type protein that had been produced in parallel, and calculated as 
e(relative)=e(variant)/e(wild-type)*100.  
 
Structural analyses.  
Function-structure evaluations were performed with an updated model of human MutLα 
(MLH1-PMS2) ⁠
9
 based on the N-terminal domains of human PMS2 NTD 
24
 and an homology 
model of MLH1-NTD 
23
. The C-terminal domains (CTD) were built by homology modeling 
using yeast MutLα (PDB codes: 4E4W and 4FMN) and human MLH1 (PDB code: 3RBN) 
structures as templates. 4E4W, the highest resolution yeast MutLα structure, was used for 
modeling the conformation of the dimeric interface and as a template for modeling missing 
regions of MLH1 and the whole PMS2 subunit. 4FMN was used to model one loop missing 
from 4E4W structure. The MIP-box peptide (a fragment of NTG2) was taken from 4FMN 
structure and the zinc ions from 4E4W. The modeling templates were identified and selected 
using MODexplorer 
25
. The target-template alignment used for modeling PMS2 was evaluated 
and refined using MODalign 
26
. The final model was constructed after exporting the 
alignments from MODexplorer and MODalign and running Modeller 
27
 on a hybrid template 
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containing all necessary fragments from the selected templates, the MIP-box, and zinc ions. 
Figures were generated using PyMOL v.1.4.1 (Schrödinger LLC). 
 
 
Results 
Testing of nine small coding MLH1 variants identified in nine South American cancer 
patients.  
Nine small coding variants identified in nine CRC patients from South America were chosen 
for analysis (Table 1). Of these, five have not been reported before. Three of the previously 
described variants have been listed in InSiGHT class 3, meaning that their pathogenic 
potential is unclear. Only one variant (p.Lys618del), for which sufficient clinical data is 
available, has been classified pathogenic (class 5). We included this variant in our analysis as 
an additional pathogenic control. 
Although family cancer disease information was available for six variant carriers 
(Supplementary Figure S1), it was not possible to perform additional genetic analyses in 
their relatives to assess cosegregation, which is a highly reliable method for the assessment of 
pathogenicity. Moreover, no sufficient information on molecular tumor traits (microsatellite 
instability and BRAF status) could be used for pathogenicity classification by Bayesian 
integrative multifactorial analysis ⁠
6
 (Table 1). For assessing pathogenicity, we therefore had 
to rely on alternative ways, primarily functional testing of the genetic variants in vitro.  
 
Functional analysis of the MLH1 variants.  
Loss of protein stability (resulting in absence of protein) and loss of repair activity are both 
directly associated with disease. Therefore, testing these parameters provides significant 
information for pathogenicity assessment.  
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The most frequent consequence of small coding alterations in MLH1 has been shown to be a 
decrease of the protein stability, which can be determined by expression of the variant cDNA 
11
. Decreases in protein stability entail lower protein levels, which, even if the protein is 
functional, causes loss of repair activity below a certain threshold 
11,28
. In order to translate 
expression defects into pathogenicity statements, we used previously established reference 
variants 
11
. We applied reference variant MLH1 p.Ala681Thr, which allows to identify 
variants whose destabilization is severe enough to confer a pathogenic effect in humans due to 
the low cellular protein levels. Additionally, the neutral polymorphism MLH1 p.Val716Met 
was used as a reference for clinically neutral defects of stability 
11
. 
We thoroughly assessed the expression levels of all variants in direct comparison to wildtype 
MLH1 protein and the two reference variants (Figure 1A). Results of several independent 
experiments were analyzed (Figure 1B). Six of the variants were at least as strongly 
expressed as the wildtype protein and therefore do not display stability problems. In contrast, 
three variants displayed stability decreases similar or stronger than the reference variant: 
p.Arg265Pro, p.Lys618del and p.Leu676Pro. In two of these cases, expression was 
significantly below the reference variant for pathological expression defects (p<0.05). For 
these strongly destabilized variants, a pathogenic defect can be concluded since insufficient 
MLH1 protein is available in the cell 
11
. 
Another major reason for pathogenicity of small coding MLH1 variants is when these confer 
catalytic inactivity of the variant MLH1 protein. Since the major task of MLH1 protein is 
supporting DNA mismatch repair, we assessed the ability of the variants to perform the repair 
reaction in vitro (Figure 2A). Several independent experiments were performed to validate 
the results (Figure 2B). 
Four of the variant proteins were indistinguishable from wildtype in this analysis, while only a 
residual repair signal identical to the negative control sample demonstrated that four variants 
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had fully lost repair activity (p.Tyr97Asp, p.Arg265Pro, p.Lys618del and p.Leu676Pro). One 
variant (p.His112Gln) showed slightly reduced activity.  
 
Conservation and structural roles of the affected residues. Analysis of the structural 
positions and conservation of variant residues can explain and thereby confirm the functional 
results of mutational studies. We therefore analyzed the conservation and considered the 
positions of the affected residues in a structural model of the MutLα heterodimer (Figure 3).  
Tyr97 is located in the “ATP lid”, a highly conserved structure vital for functionality of the 
ATPase 
29–31
. The non-conservative substitution of tyrosine to aspartate is expected to disturb 
the ATPase, explaining the observed loss of catalytic function and corroborating a pathogenic 
effect. 
His112 is located in an extensive β-sheet that forms the back of the ATPase pocket. This 
residue is involved in interaction of MLH1 with the MutSα 
23
. While inversion of the side-
chain charge abolished interaction and rendered MLH1 DNA repair deficient 
23
, the less 
drastic substitution to glutamine described here had a milder effect on DNA repair. 
Pro141 is in a similar position, albeit on the other side of the β-sheet. A specific role in 
protein structure or function is not obvious. Moreover, alanine is frequently present in this 
position in other organisms (Table 2 and Supplementary Figure S1), strongly suggesting 
that it is a neutral substitution, which is confirmed by the biochemical results. 
Arg265 is located in a highly conserved loop. It establishes a side-chain hydrogen bond to the 
ATPase pocket. Therefore, it has been suggested to be a detector switch that transmits 
ATPase signals to conformational changes 
30
. A substitution of this highly relevant residue to 
serine has been described before and was also found to abolish repair activity 
32
. Since the 
residue exerts its biochemical effects through its side chain, the mutation to proline can be 
expected to display an even more damaging defect, explaining the biochemical loss of 
function of the variant and corroborating a pathogenic effect. 
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Asn338 is located in the unstructured linker connecting the N- and C-terminal domains. This 
linker is not conserved nor crystallized and therefore not present in the structural model. This 
alone argues against a relevant role of Asn338 in MLH1. Moreover, substitutions for serine in 
this position are present in many organisms (Table 2 and Supplementary Figure S2), 
corroborating the functional finding that the substitution is neutral. 
Ile501 also belongs to this linker region, but it is present in the structure of the C-terminal 
domains. It is located in a loop, therefore its deletion does not affect secondary structure. 
Since the linker region is highly variable not only in sequence but also in length, deletions or 
insertions seem to be largely acceptable without loss of function. These considerations are in 
good agreement with the experimental finding that it did not affect biochemical functionality 
of MLH1. 
Arg575 is located in the conserved C-terminal domain. It connects a β-sheet secondary 
structure with a loop. It is located on the protein surface, and far from functional core regions 
of the CTD like the zinc-binding 
33
, dimerization 
34,35
 and endonuclease 
33,36
 domains, and it is 
poorly conserved. Moreover, this conservative substitution is also frequently present in MLH1 
proteins from other organisms (Table 2 and Supplementary Figure S3), corroborating that it 
is a neutral exchange, which is consistent with the biochemical findings. 
Deletion of lysine 618 affects the center of an α-helix. Consequently, the deletion causes a 
rotation of the C-terminal residues around the helix axis and distort the orientation of internal 
(hydrophobic) and external (hydrophilic) residues. Therefore, it can be expected to severely 
affect protein structure (and function), which is reflected by the low stability of the mutant 
protein. 
Leu676 is located in the middle of another α-helix, within a conserved structural three-helix 
motif that we have shown before to be very sensitive to substitutions which regularly cause 
severe protein destabilization 
11
. Therefore, the functional finding of severe instability is fully 
consistent with this substitution to the structure breaker amino acid proline. A different 
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substitution of this position (Leu676Arg) has been found to have the same defect before and 
was therefore considered pathogenic 
11
.  
 
 
Comprehensive evaluation of evidence. 
In the Amsterdam-positive family from Uruguay (Uru-8249/Uru-8461, Supplementary 
Figure S4), 11 directly related individuals in three generations were affected by CRC, with an 
average age of onset of 47 years. The index patient (carrier of the p.Tyr97Asp alteration) was 
diagnosed with CRC at 42 years. The high penetrance of Lynch-syndrome-associated cancers 
in the family and the low average age of onset strongly suggest a hereditary cause, and the 
finding that p.Tyr97Asp inactivates DNA mismatch repair strongly suggests that this 
alteration is the causative factor. 
The index patient of family Arg-39 carries two alterations, the substitutions p.His112Gln and 
p.Arg575Lys. There are two CRC cases in the family, who does not meet the Amsterdam II 
criteria. Since it was not possible to retrieve material from the family for determining allelic 
positions of the two variants, these were considered individually. While one variant is highly 
likely neutral, the clinical outcome of the other, biochemically compromised variant 
(p.His112Gln) remains unclear. The comparatively low penetrance of Lynch-syndrome-
associated cancers in the family, however, rather suggests a moderate, if any, pathogenic 
effect. Another observation that supports neutrality of this variant is its frequency in some 
control populations, which approximates the general incidence of Lynch syndrome (Table 1): 
it is present at a rate of 1:8650 in East Asia, while the general incidence of Lynch syndrome, 
i.e. all pathogenic mutations in all relevant genes, has been estimated to 1:660-1:2200; 
37
.  
One individual from Colombia carried the MLH1 p.Pro141Ala, for which we did not find 
biochemical evidence for conferring a loss of function. Moreover, alanine in this position 
seems evolutionary acceptable because it occurs naturally in MLH1 proteins of 8% of all 
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analyzed organisms (Table 2), strongly suggesting neutrality of this substitution. 
Additionally, the variant showed co-occurrence in the carrier with a pathogenic mutation in 
MSH2. While this invalidates use of the medical data for interpretation of the specific effect 
of Pro141Ala, co-occurrence of a pathogenic variant with an unclear variant is generally 
considered to make pathogenicity less likely for the unclear variant 
38
. 
In the Amsterdam-positive family Chi-43, 10 of 41 individuals were affected from Lynch-
syndrome-associated neoplasms in 4 generations, with an average age of onset of 25 years. 
This family record is highly suspicious for Lynch syndrome, and the finding that the 
identified alteration (p.Arg265Pro) abolished the biochemical function of the protein 
consistently speak in favor of pathogenic effect in humans. 
A comparatively young Brazilian CRC patient (38 years at diagnosis) was found to carry a 
variant causing the p.Asn338Ser substitution in MLH1. While MSI has been observed in the 
tumor of a German carrier of this variant 
39
, all other information on this variant suggest 
neutrality. Therefore, the singular observation of MSI in one tumor probably has been 
coincidence caused by somatic loss of mismatch repair, for example by MLH1 
hypermethylation. 
Another Brazilian CRC patient of 60 years of age carried a three-nucleotide deletion causing 
the loss of one amino acid (isoleucine 501) from the MLH1 protein. The consequences of 
amino acid deletions are, in general, expected to be worse and harder to predict than 
substitutions. However, this deletion had no impact on biochemical performance of MLH1, 
and this was in good agreement with the low conservation and structural position of the 
deleted residue at the end of the highly variant linker region of MLH1. We therefore consider 
it to be likely neutral. 
In contrast, the other one-residue deletion in this study (p.Lys618del) was found in an 
Amsterdam-positive family from Argentina with multiple first-degree relatives with colorectal 
carcinoma (Arg-43; average age at cancer diagnosis: 44 years). Biochemical evidence 
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confirms that the variant is defective. The variant p.Lys618del has already been classified in 
class 5. 
Finally, in two Amsterdam-positive Brazilian families (BRA-1 and SL-36D) who presented 
in summary with 8 cancer cases in 26 recorded members (average age of onset 48 years) the 
index patients carried the alteration p.Leu676Pro. Molecular tumor data (MSI, IHC) are at 
odds (Table 1), but the variant has not been found in 280 healthy controls 
15
. In our analysis, 
this alteration abrogated stability and repair activity of MLH1, strongly suggesting causality 
for the cancer predisposition in these two families. 
 
 
Discussion  
Pathogenicity classification of small coding MLH1 variants is sometimes straightforwardly 
possible if sufficient clinical data is available. However, so-called private variants (rare 
variants with little clinical and family information) may fail in established classification 
approaches and then require alternative methods for pathogenicity assessment. Here, we 
evaluated a series of small coding MLH1 variants identified in South American patients 
suspected to have Lynch syndrome. While extensive information on cancer cases in the 
families was available from some of the affected individuals, genetic testing has only been 
performed in the index individuals, and practically no molecular tumor data was available. 
Therefore, although even little clinical information can sometimes facilitate classification by 
integrative analysis 
10
, this was not possible in these cases. 
We therefore had to rely on functional analysis in combination with other lines of evidence to 
approach a classification for these variants and facilitate diagnosis for the affected families. 
We used a previously established robust method that allows to deduce pathogenicity 
information from functional evidence, and also used other lines of evidence (from 
evolutionary information, protein structure and family clinical data). Comprehensive analysis 
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showed that evidence for pathogenicity or neutrality was consistent: it coherently supported 
that two alterations confer a pathogenic effect by catalytic inactivation (the two ATPase 
mutations, p.Tyr97Asp and p.Arg265Pro). For two further alterations, consistent evidence 
suggested a pathogenic effect by destruction of protein integrity (p.Lys618del and 
p.Leu676Pro). 
Conversely, findings for another four variants coherently supported neutrality: they showed 
no detectable defects in functionality. While this finding is usually hampered by the caveat 
that the applied biochemical assay system may not reflect all aspects of biological function, in 
these cases we also found that the investigated patient substitutions occur quite frequently in 
evolution. This observation strongly supports neutrality similarly to finding a significant 
frequency of a given variant in unaffected control populations. Moreover, one variant 
(Pro141Ala) co-occurred with a clearly pathogenic variant in its carrier (Table 1), which is 
also considered a strong indicator of neutrality. 
Just one variant remained for which neither functional nor other evidence gave a clear result: 
for p.His112Gln, functional data showed intermediate results which would require more 
sensitive reference variants to determine if the effects will result in a clinical phenotype.  
Taken together, the analysis of biochemical function, performed with suitable controls 
enabling clinically meaningful result readout, in conjunction with additional evidence is able 
to yield a reliable pathogenicity statement if coherent results are achieved. This approach may 
therefore step in to the breach if other ways of classification fail to provide sufficient 
evidential value. 
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Figure legends 
Figure 1: Analysis of expression of the MLH1 variants. 
A: Expression of wildtype and variant MLH1 proteins was visualized by SDS-PAGE and 
western blotting. The two stability reference variants Ala681Thr (pathogenic expression 
defect) and Val716Met (non-pathogenic expression defect, polymorphism) were transfected 
in parallel. The shown blots are representative for 9 independent experiments that were 
performed and delivered the data shown in evaluation (Figure 1B). 
B: Average expression values in percent of the wildtype expression, standard deviations and 
results of the t-test of 9 independent experiments are shown for wildtype and variant MLH1 
protein expression. The column of the reference variant for a pathogenic expression defect 
(p.Ala681Thr) is hatched, expression levels significantly below the dotted line established by 
this reference variant represent pathogenic stability defects of the variant protein (Lys618del 
and Leu676Pro). 
 
Figure 2: Analysis of mismatch repair activity of the MLH1 variants.  
DNA mismatch repair activity was assessed for wildtype and variant MLH1 proteins, and a 
negative control (without MLH1 protein) was included as detailed in Materials and Methods. 
A. The extent of repair is visible in the agarose gel electrophoresis by the generation of 2 
smaller fragments of the (unrepaired) linearized plasmid. This is shown in the representative 
agarose gel image (composed of three experiments since always 6 samples were processed in 
parallel).  
B. Between 3 and 9 independent experiments were performed for each variant, and repair 
activity was scored relative to wildtype MLH1 protein (100%). Average repair values and 
standard deviations are shown. 
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Figure 3. Structural positions of affected residues in the MutLα heterodimer. The model 
is shown in cartoon presentation, comprising the N-terminal (aa 1-331) and C-terminal (aa 
488-756) domains of MLH1 (green) and the corresponding partner domains PMS2 (right 
side). The MLH1 subunits are rotated by 90° on the left side to improve presentation of the 
residues studied (shown as red balls). The ADP- Mg
2+
 bound by the MLH1 ATPase is shown 
in blue, the zinc ions of the exonuclease domain in orange. The locations of residues affected 
by alterations are indicated by red balls representing the alpha carbon atoms. For the two 
deletion variants, Ile501del and Lys618del, it is impossible to properly indicate the affected 
residue because both occur in the context of two (Ile500-Ile501) or three (Lys616-Lys617-
Lys618) repetitions of the same amino acid; in these cases, only the residue with the lowest 
number is indicated. 
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Figure 2: Analysis of mismatch repair activity of the MLH1 variants.  
DNA mismatch repair activity was assessed for wildtype and variant MLH1 proteins, and a negative control 
(without MLH1 protein) was included as detailed in Materials and Methods. A. The extent of repair is visible 
in the agarose gel electrophoresis by the generation of 2 smaller fragments of the (unrepaired) linearized 
plasmid. This is shown in the representative agarose gel image (composed of three experiments since 
always 6 samples were processed in parallel).  
B. Between 3 and 9 independent experiments were performed for each variant, and repair activity was 
scored relative to wildtype MLH1 protein (100%). Average repair values and standard deviations are shown. 
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Table 1: 
Clinical and genetic information of the investigated South American patients. 
 
Familiy 
ID 
Origin Clini
cal 
cri-
teria 
Index patient (tumor) 
information 
Alteration 
(gDNA) 
Alteration 
(Protein) 
Population 
frequency (Exac 
database) 
 
Previous 
reports of the 
variant 
Uru-
8249 
Uru-
8461 
Uruguay ACII 
ACII 
CRC 42 y, MSI-L 
CRC 52 y, MSI-L 
c.289T>G p.Tyr97Asp n.r.  Dominguez-
Valentin et al. 
2013, Rossi et 
al. 2017 
Arg-39 
Argentina ACI CRC 54 y, MSI-H, IHC: 
normal MMR 
c.336T>A p.His112Gln 0.0001156 (East 
Asia) 
0.0000864 (Latino) 
Dominguez-
Valentin et al. 
2013, Rossi et 
al. 2017 c.1724G>A p.Arg575Lys n.r. 
UN-23 Colombia ACII CRC 45 y; additional 
pathogenic alteration: 
MLH1 c.1856delG 
c.421C>G p.Pro141Ala n.r. Giraldo 2005; 
Chao 2002;  
Rossi et al. 
2017 
Chi-43 Chile ACII CRC 25 y c.794G>C p.Arg265Pro n.r. Rossi et al. 
2017 
1  Brazil ACII 38 y c.1013A>G p.Asn338Ser 0.0000902 
(European) 
0.0000607 (South 
Asian) 
Rossi 2002; 
Tournier 
2008; Hardt 
2011; 
2  Brazil ACII 60 y c.1500_1502delC
AT 
rs587778920 
 
p.Ile501del 
 
0.0000864  
(Latin America) 
Rossi 2002 
Valentin 2011 
Rossi et al. 
2017 
Arg-43 Argentina ACI CRC 44 y IHC: Loss 
MLH1, MSI-H 
c.1852_1854delA
AG 
p.Lys618del n.r. InSIGHT 
BRA-1 
 
Brazil 
 
ACI CRC 53 y; BRAF 
wildtype, MSI-H, IHC: 
Loss MLH1/PMS2  
c.2027T>C 
 
p.Leu676Pro 
 
n.r. 
0/280 
Hardt 2011; 
Dominguez-
Valentin et al. 
2013, 
Carneiro 
2015; 
Rossi et al. 
2017 
 
SL-36D ACI CRC 43 y, BC 50 y, IHC 
normal, MSS. 
 
Abbreviations: CRC, colorectal carcinoma. BC: breast cancer. IHC, immunohistochemistry results. MSI-H, 
microsatellite instability-high in tumor (when ≥ 2 markers where unstable. MSI-L: microsatellite instability low 
(when one of the markers was unstable). MSS, microsatellite stable (when none of the markers were unstable). 
GC, gastric cancer. ACI/ACII: family meets Amsterdam criteria I or II; n.r., not reported; n.a., not applicable; 
n.d., no data. 
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Table 2.  
Summary of the analyses on the variants 
 
 
 
Abbreviations: InSiGHT: International Society for Gastrointestinal Hereditary Tumors; UMD: Universal mutation database; UV: Unclassified variant; US: Uncertain significance; LP: likely pathogenic. 
Alteration (gDNA) Alteration 
(Protein) 
Evolutionary information Structural information 
relevant for pathogenic 
potential 
Biochemical 
effect(s) 
(stability/functionality) 
Database classifications Proposed 
classification 
Classification based on 
InSiGHT UMD ClinVar 
c.289T>G p.Tyr97Asp Highly conserved (8/9) 
 
ATPase involved, 
functional loss plausible 
Stable 
Non-functional  
- - US Likely pathogenic Biochemistry, conservation, structure. 
C.336T>A p.His112Gln Highly conserved (8/9);  
Gln rarely in this position (1%) 
 Stable  
Compromised 
- - - Unclear 
 
 
c.1724G>A p.Arg575Lys Intermediate conservation (5/9); 
Lys occurs in this position (13%) 
No effect on protein 
function plausible 
Stable 
Functional  
- - - Likely neutral 
 
Biochemistry,  
evolutionary occurrence, structure. 
c.421C>G p.Pro141Ala Intermediate conservation (6/9); 
Ala occurs in this position (8%) 
No effect on protein 
function plausible 
Stable  
Functional  
3 - US Likely neutral Biochemistry,  
evolutionary occurrence,  structure.  
c.794G>C p.Arg265Pro Highly conserved (8/9) ATPase involved, 
functional loss plausible 
Unstable (=A681T) 
Non-functional 
- - LP Likely pathogenic Biochemistry, conservation, structure. 
c.1013A>G p.Asn338Ser Intermediate conservation (7/9); 
Ser occurs in this position (7%) 
No effect on protein 
function plausible 
Stable 
Functional  
3 UV US Likely neutral Biochemistry,  
evolutionary occurrence,  structure. 
c.1500_1502delCAT 
rs587778920 
 
p.Ile501del Intermediate conservation (4/7); 
Indels occur in linker 
No effect on protein 
function plausible 
Stable 
Functional  
- - US Likely neutral Biochemistry, conservation, structure. 
c.1852_1854delAAG p.Lys618del Intermediate conservation (4/7); 
No Indels: Lys615-Met621 
Protein distortion highly 
likely 
Unstable (<A681T)** 
Non-functional 
5 Causal Patho-
genic 
Pathogenic Biochemistry, length conservation, 
structure. 
c.2027T>C p.Leu676Pro Intermediate conservation (6/9); Loss of stability plausible 
Arg variant has same effect 
Unstable (<A681T)** 
Non-functional 
3 - US Likely pathogenic Biochemistry, structure; observation of 
another pathogenic substitution in this 
position. 
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